This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharma marketing. From generative AI tools that draft emails to predictive algorithms that segment target audiences, the speed and scale of innovation are staggering. But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster?
Federal health officials said Tuesday they are pulling back $11.4 billion in COVID-19-related funds for state and local public health departments and other health organizations throughout the nation. “The COVID-19 pandemic is over, and HHS will no longer waste billions of taxpayer dollars responding to a non-existent pandemic that Americans moved on from years ago,” the U.S.
The US Food and Drug Administration (FDA) has approved Blujepa ( gepotidacin ) antibiotic for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients aged 12 years old and over. The first-in-class bactericidal drug is indicated for such infections caused by E scherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.
On a recent Friday evening, it struck me: I needed to speak to a neurosurgeon. I was watching someone root around in actor Adam Scott’s head on an episode from the second season of “Severance” on Apple TV+. (Note: This post and podcast episode contain spoilers for “Severance.” You’ve been warned.) I needed to know: How realistic is the brain surgery that gives the show its name and premise?
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Big pharma is eyeing Australias Pharmaceutical Benefits Scheme, as they lobby Donald Trump to demand higher prices for their medicines. Anthony Albanese has promised to bring down the price of PBS-listed medicines to no more than $25 a script, while the Coalition has already pledged to match it if they return to government. Senior reporter Tory Shepherd speaks to Reged Ahmad about the politics of our affordable medicines You can support the Guardian at theguardian.com/fullstorysupport Read more:
In recent months, a new kind of partnership between telehealth companies and pharmaceutical manufacturers has come under scrutiny over concerns that such arrangements could lead to inappropriate prescriptions and poor care. Eli Lilly and Pfizer, along with five telehealth companies accessible through the pharma companies’ websites, have recently received letters from four senators echoing those concerns, asking questions about care, prescription volume, and the flow of data and money betw
Cold Chain Technologies (CCT), a global provider for temperature-sensitive packing and digital solutions, has acquired Global Cold Chain Solutions (GCCS), a provider of passive cold chain solutions primarily in Australia and India. Based in Massachusetts, US, the deal furthers CCT’s reach to South Asia and Oceania, where there is vast investment in life sciences verticals. […] The post Cold Chain Technologies acquires Global Cold Chain Solutions appeared first on Pharmafile.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Cold Chain Technologies (CCT), a global provider for temperature-sensitive packing and digital solutions, has acquired Global Cold Chain Solutions (GCCS), a provider of passive cold chain solutions primarily in Australia and India. Based in Massachusetts, US, the deal furthers CCT’s reach to South Asia and Oceania, where there is vast investment in life sciences verticals. […] The post Cold Chain Technologies acquires Global Cold Chain Solutions appeared first on Pharmafile.
You’re reading The MAHA Diagnosis , a STAT series that examines the major elements of the Make America Healthy Again movement led by Robert F. Kennedy Jr. From cancer warning labels to soda taxes , progressive states like California and New York have long led the way on legislation meant to improve public health. Now the Make America Healthy Again movement is prompting lawmakers in more conservative states, like Texas, Florida, Oklahoma, and Utah, to join blue ones in introducing bills th
Coronado Research, a UK-based consultancy-led organisation, has announced that it has appointed Gary Lyons as executive vice president (EVP) for medical affairs. Lyons is a medical affairs leader, with experience in senior positions in pharmaceutical, consultancy and agency sectors. He has worked on developing medical communication services locally and globally.
The National Institutes of Health on Wednesday placed deputy director Tara Schwetz on administrative leave, according to a source familiar with the decision, marking the third time a senior leader has departed the agency since the Trump administration took power roughly nine weeks ago. Schwetz had served as deputy director for coordination, planning, and strategic initiatives, a position she has held since late 2023.
Allegro has announced that hydrocelin, its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies. Allegro is a biomedical company that develops nanotechnology-based treatments for degenerative joint disease. The preclinical studies were conducted in rats for periods of four and 13 weeks, respectively. Hydrocelin was injected into four separate locations, and a […] The post Allegro shares promising preclinical results for osteoarthritis treatment appeared
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Y ou’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday. My colleague Casey Ross has been reporting on AI in health care since before it was cool (remember IBM’s Watson ?
Pharming Group has announced that the first patient has been dosed in a phase 2 clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation. The company, based in Leiden, the Netherlands, specialises in developing and commercialising medicines for patients with rare, debilitating and life threatening diseases.
Jasmine Cutler, PharmD, CPh, assistant professor in the department of pharmacy practice at the Taneja College of Pharmacy, discusses role of education and accessibility in reproductive health.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The Centers for Disease Control and Prevention is reportedly rescinding $11.4 billion in funds to states, cities and organizations receiving grants for COVID-19 efforts.
To prepare for the expansion, Two Chairs has added new clinicians to its team, including some who are cross-licensed to treat in multiple states. To date, the company focused on building its presence in California, Florida and Washington, where it also has in-person clinics.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Susan Cornell, PharmD, CDCES, FAPhA, FADCES, associate director of experiential education at the College of Pharmacy at Midwestern University, also addresses personalized care and the expanding responsibilities of pharmacists.
Using Janus kinase inhibitors, having experienced a previous thrombosis episode, and higher age were associated with a heightened risk of a new thromboembolic event.
Older age and being insured with Medicare or Medicaid were associated with heightened annual joint bleeding rates, whereas treatment in the Northeast United States improved outcomes in both hemophilia A and hemophilia B.
Private equity's track record in healthcare could best be described as "mixed," with high-profile failures like the implosion of Steward Health Care setting a poor example. | Private investment will be even more critical for healthcare organizations in a political environment where public funds are likely to shrink.
Dual-eligible beneficiaries are among the most expensive and complex patients out there. | Pair Team supports community-based organizations via California's Medi-Cal Community Care Hubs model.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content